Sarepta Therapeutics Shares Clinical Data and Integrated Analysis for SRP-9001, its investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

Sarepta has just presented new results and analyses that demonstrate a consistent, and statistically significant functional benefit of their gene-therapy product SRP-9001 in Duchenne patients versus a propensity-weighted external natural history control. 

The new data from studies 101, 102 and 103 demonstrated consistently meaningful results and importantly demonstrated sustained functional benefit over the 2- and 4-year timeframe.  

The safety profile was consistent with that previously reported; there was one incidence of myocarditis that resolved after treatment and no clinically relevant complement activation was observed. 

The full company press release can be found here.

Related Posts

Share This Page

Make an Impact

You can advance the care, treatment and cure for Duchenne muscular dystrophy. Contributions in any amount can truly make a difference and can be credited to a fundraiser or event from the list below.